Evidence map›Paper›PMID 41285779›Full record

ArticleNature communications2025

GII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes.

Kentaro Tohma, Sonja Jacobsen, Britta Altmann, Joseph A Kendra, Michael Landivar, William E De La O, Maria Dolores Fernandez-Garcia, Karina A Gomes, Sophia Chudnovsky, Lauren A Ford-Siltz and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Phylogenetic Analyses ofMicroorganisms · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kentaro TohmaDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. kentaro.tohma@fda.hhs.gov.ORCID http://orcid.org/0000-0002-0456-9355
Sonja JacobsenDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Britta AltmannDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Joseph A KendraDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0001-5886-7377
Michael LandivarDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
William E De La ODivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Maria Dolores Fernandez-GarciaEnterovirus and Viral Gastroenteritis Unit, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0003-0336-6596
Karina A GomesLaboratory of Viral Gastroenteritis, INEI-ANLIS "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.ORCID http://orcid.org/0009-0001-1222-8470
Sophia ChudnovskyDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Lauren A Ford-SiltzDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Kelsey A PilewskiDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Yamei GaoDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Ilya MazoFDA HIVE, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Sandra NiendorfDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Gabriel I ParraDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. gabriel.parra@fda.hhs.gov.ORCID http://orcid.org/0000-0002-1102-4740

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two years, increased norovirus activity has been reported in multiple countries, accompanied by a rise in genotype GII.17 prevalence. Despite causing large outbreaks in Asia during 2014-2016, GII.17 has not historically been considered a predominant genotype. In this study, using 1471 archival and newly-identified GII.17 genomes, we investigated (i) global diversification patterns of this virus at the whole-genome level, (ii) in-depth mutational patterns within 511 viruses detected during a 10-year national survey in Germany, and (iii) intra-host viral diversity and adaptation processes that lead to the predominance of the GII.17 virus. The recent GII.17 norovirus exhibited extensive genetic diversity and multiple back-and-forth and recurrent mutations during the early phase of its epidemic; however, this diversity declined by 2024, suggesting that the virus had reached a phenotype efficient for human infection. Experimental data confirmed that mutations in the viral capsid enhanced binding to host factors associated with virus entry and resulted in antigenic changes compared to previously circulating clusters. Overall, this study demonstrated that the recent surge of GII.17 resulted from a dynamic, multifaceted process involving diverse adaptive strategies, ultimately enabling the virus to achieve sustained transmission within the human population.

Indexed as

Caliciviridae InfectionsEvolution, MolecularGastroenteritisNorovirusCapsid ProteinsDisease OutbreaksGenetic VariationGenome, ViralGenotypeGermanyHumansMutationPhylogenyCapsid Proteins

Identifiers

PMID41285779
PMCPMC12749941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.